CN103393114A - 以青稞红曲为主降脂养心增强免疫力的制剂及制备方法 - Google Patents
以青稞红曲为主降脂养心增强免疫力的制剂及制备方法 Download PDFInfo
- Publication number
- CN103393114A CN103393114A CN2013103400463A CN201310340046A CN103393114A CN 103393114 A CN103393114 A CN 103393114A CN 2013103400463 A CN2013103400463 A CN 2013103400463A CN 201310340046 A CN201310340046 A CN 201310340046A CN 103393114 A CN103393114 A CN 103393114A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- highland barley
- immunity
- barley monascus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000228347 Monascus <ascomycete fungus> Species 0.000 title claims abstract description 39
- 235000007340 Hordeum vulgare Nutrition 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 239000002994 raw material Substances 0.000 title claims abstract description 12
- 240000005979 Hordeum vulgare Species 0.000 title abstract 4
- 239000000284 extract Substances 0.000 claims abstract description 44
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 230000036039 immunity Effects 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 23
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 5
- 229940119485 safflower extract Drugs 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 241000209219 Hordeum Species 0.000 claims description 34
- 244000020518 Carthamus tinctorius Species 0.000 claims description 16
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 16
- ILRCGYURZSFMEG-RKQHYHRCSA-N Salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RKQHYHRCSA-N 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 5
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 3
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims description 3
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229930187479 gypenoside Natural products 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 15
- 150000002632 lipids Chemical class 0.000 abstract description 12
- 241001165494 Rhodiola Species 0.000 abstract description 9
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 7
- 241000222336 Ganoderma Species 0.000 abstract description 6
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 6
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 239000000825 pharmaceutical preparation Substances 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 230000002929 anti-fatigue Effects 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 210000000748 cardiovascular system Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241001065361 Gynostemma Species 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000003516 hyperlipidaemic effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000496 anti-anoxic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别(剂量) | 数量(只) | 游泳时间(min) |
对照组0.0g/kg | 10 | 7.04±2.27 |
小剂量组0.6g/kg | 10 | 10.56±5.75 |
中剂量组1.2g/kg | 10 | 11.53±4.77* |
大剂量组1.8g/kg | 10 | 12.49±7.11* |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310340046.3A CN103393114B (zh) | 2013-08-06 | 2013-08-06 | 以青稞红曲为主降脂养心增强免疫力的制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310340046.3A CN103393114B (zh) | 2013-08-06 | 2013-08-06 | 以青稞红曲为主降脂养心增强免疫力的制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103393114A true CN103393114A (zh) | 2013-11-20 |
CN103393114B CN103393114B (zh) | 2016-01-13 |
Family
ID=49557011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310340046.3A Active CN103393114B (zh) | 2013-08-06 | 2013-08-06 | 以青稞红曲为主降脂养心增强免疫力的制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103393114B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107058431A (zh) * | 2017-05-09 | 2017-08-18 | 王智森 | 一种红景天液体深层发酵生产红景天苷的方法 |
CN110368487A (zh) * | 2019-08-09 | 2019-10-25 | 上海医盛生物科技发展有限公司 | 一种改善心脑血管健康状况的功能性营养食品 |
CN111202207A (zh) * | 2020-01-19 | 2020-05-29 | 西藏达热瓦青稞酒业股份有限公司 | 一种青稞发酵食品及其制备方法 |
CN111202197A (zh) * | 2020-01-19 | 2020-05-29 | 西藏达热瓦青稞酒业股份有限公司 | 一种青稞发酵饮料的制备方法及其制备的青稞发酵饮料 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541005B1 (en) * | 2000-06-15 | 2003-04-01 | A. Glenn Braswell | Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis |
CN1739532A (zh) * | 2004-08-26 | 2006-03-01 | 谢永杰 | 西洋参绞股蓝总皂甙制剂 |
CN1876042A (zh) * | 2006-04-26 | 2006-12-13 | 闫聿逊 | 一种降脂药物的配制方法 |
CN101455359A (zh) * | 2008-12-31 | 2009-06-17 | 西藏月王生物技术有限公司 | 一种活血降脂益寿的口服制剂及制备方法 |
CN102599501A (zh) * | 2012-03-15 | 2012-07-25 | 宋靖钢 | 降脂护肝的保健食品红洋胶囊或片剂 |
-
2013
- 2013-08-06 CN CN201310340046.3A patent/CN103393114B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541005B1 (en) * | 2000-06-15 | 2003-04-01 | A. Glenn Braswell | Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis |
CN1739532A (zh) * | 2004-08-26 | 2006-03-01 | 谢永杰 | 西洋参绞股蓝总皂甙制剂 |
CN1876042A (zh) * | 2006-04-26 | 2006-12-13 | 闫聿逊 | 一种降脂药物的配制方法 |
CN101455359A (zh) * | 2008-12-31 | 2009-06-17 | 西藏月王生物技术有限公司 | 一种活血降脂益寿的口服制剂及制备方法 |
CN102599501A (zh) * | 2012-03-15 | 2012-07-25 | 宋靖钢 | 降脂护肝的保健食品红洋胶囊或片剂 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107058431A (zh) * | 2017-05-09 | 2017-08-18 | 王智森 | 一种红景天液体深层发酵生产红景天苷的方法 |
CN110368487A (zh) * | 2019-08-09 | 2019-10-25 | 上海医盛生物科技发展有限公司 | 一种改善心脑血管健康状况的功能性营养食品 |
CN111202207A (zh) * | 2020-01-19 | 2020-05-29 | 西藏达热瓦青稞酒业股份有限公司 | 一种青稞发酵食品及其制备方法 |
CN111202197A (zh) * | 2020-01-19 | 2020-05-29 | 西藏达热瓦青稞酒业股份有限公司 | 一种青稞发酵饮料的制备方法及其制备的青稞发酵饮料 |
Also Published As
Publication number | Publication date |
---|---|
CN103393114B (zh) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104644915A (zh) | 一种治疗酒精性肝病的药物组合物及其制备方法和用途 | |
CN103393114B (zh) | 以青稞红曲为主降脂养心增强免疫力的制剂的制备方法 | |
CN102145128A (zh) | 一种防治心脑血管疾病的药物组合物及其制备方法 | |
CN103479691B (zh) | 降脂保肝中药组合物 | |
CN101243882B (zh) | 具有降血脂功能的保健食品及其制备方法 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN103800352B (zh) | 一种抗非酒精性脂肪性肝病的中药有效成分复方制剂及应用 | |
CN101810337A (zh) | 三七灵芝黄芪保健食品 | |
CN101214319B (zh) | 一种调节血脂的中药保健品及其制备方法 | |
CN103705578B (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
CN102631425B (zh) | 一种治疗血脂异常的蒙药 | |
WO2020097963A1 (zh) | 一种治疗高脂血症的中药组合物 | |
CN102178759B (zh) | 一种治疗风湿病的中药组合物及其制备方法 | |
CN101317900B (zh) | 一种防治酒精性肝损伤的中药组合物及制备方法 | |
CN101480472B (zh) | 调血脂的药物及生产方法 | |
CN103566349B (zh) | 一种治疗高血糖高血脂的药物组合物 | |
CN103301380B (zh) | 一种疏肝理气的中药组合物及其制备方法 | |
CN101053598B (zh) | 一种防治心脑血管疾病及糖尿病的药物组合物 | |
CN103585545A (zh) | 一种治疗中耳炎的中药组合物 | |
CN115487260B (zh) | 一种治疗高胆固醇血症或动脉粥样硬化的中药组合物及其应用 | |
CN102631486B (zh) | 一种保健组合物 | |
CN107596013A (zh) | 一种玛咖的提取方法及其制备的男性保健品 | |
CN102631492A (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN102631506B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
Wei et al. | Characteristics and Application Analysis of Proprietary Chinese Medicine Containing Chrysanthemum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170413 Address after: 850000 Lhasa economic and Technological Development Zone, Tibet City, Lhasa Road, No. 9 Patentee after: TIBET YUEWANG TIBETAN MEDICINE TECHNOLOGY CO.,LTD. Address before: 850000 Tibet autonomous region economic and Technological Development Zone, Lhasa City Road Patentee before: Tibet Yuewang Biologic Technetronic Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171025 Address after: 850000 color road, Lhasa economic and Technological Development Zone, Lhasa, Tibet Patentee after: Tibet Yuewang Biologic Technetronic Co.,Ltd. Address before: 850000 Lhasa economic and Technological Development Zone, Tibet City, Lhasa Road, No. 9 Patentee before: TIBET YUEWANG TIBETAN MEDICINE TECHNOLOGY CO.,LTD. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 850000 Lhasa economic and Technological Development Zone, Tibet City, Lhasa Road, No. 9 Patentee after: TIBET YUEWANG DRUGSTORE ECOLOGICAL TIBETAN MEDICINE TECHNOLOGY Co.,Ltd. Address before: 850000 color road, Lhasa economic and Technological Development Zone, Lhasa, Tibet Patentee before: TIBET YUEWANG BIOLOGIC TECHNETRONIC Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 850000 No. 9 Wei se Road, Lhasa economic and Technological Development Zone, Lhasa, Tibet Autonomous Region Patentee after: Xizang Hongqu Biological Co.,Ltd. Country or region after: China Address before: 850000 No. 9 Wei se Road, Lhasa economic and Technological Development Zone, Lhasa, Tibet Autonomous Region Patentee before: TIBET YUEWANG DRUGSTORE ECOLOGICAL TIBETAN MEDICINE TECHNOLOGY Co.,Ltd. Country or region before: China |